Retatrutide vs tirzepatide vs semaglutide comes down to three stages of one drug class: approved and established, approved and stronger head-to-head, and still in trials. All three act on the incretin system controlling appetite and blood sugar, but each hits a different number of hormone receptors, and the evidence behind each differs in maturity.
The Compound Universe take: Tirzepatide beats semaglutide in the one completed head-to-head trial (20.2% vs 13.7%), and retatrutide’s own phase 2 number (up to 24.2%) is the largest on the table, but it’s the only one still waiting on an FDA decision. More receptors has tracked with more weight loss so far; whether that holds up head-to-head for retatrutide is the open question.
Want the full retatrutide trial file?
Want just one compound? See the tirzepatide research summary.
| Attribute | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| What it is | Triple GIP/GLP-1/glucagon receptor agonist | Dual GIP/GLP-1 receptor agonist | Single GLP-1 receptor agonist |
| Best studied for | Obesity, and early liver-fat (MASLD) signal | Obesity and type 2 diabetes | Obesity and type 2 diabetes |
| Reported weight loss (trial average) | Up to 24.2% at 48 weeks (phase 2) [2] | Up to 22.5% at 72 weeks (SURMOUNT-1) [3] | 14.9% at 68 weeks (STEP 1) [1] |
| Evidence tier | Human phase 2 complete; phase 3 topline only | Human phase 3, plus head-to-head vs semaglutide | Human phase 3, longest real-world track record |
| US regulatory status (July 2026) | Investigational; not FDA-approved | FDA-approved (Mounjaro, Zepbound) | FDA-approved (Ozempic, Wegovy) |
What retatrutide, tirzepatide, and semaglutide actually are
All three are incretin-mimetic peptides, lab-made copies of gut hormones that slow stomach emptying, cut appetite, and improve blood sugar control.
Receptor count is the difference:
- Semaglutide: one receptor (GLP-1)
- Tirzepatide: two receptors (GLP-1 and GIP)
- Retatrutide: three receptors (GLP-1, GIP, and glucagon), why Eli Lilly calls it a “triple hormone receptor agonist,” not a GLP-1 drug [2]
Retatrutide, tirzepatide, and semaglutide by weight-loss evidence
Semaglutide: the first approved GLP-1 for weight management
STEP 1 found once-weekly semaglutide 2.4 mg produced a mean 14.9% weight reduction over 68 weeks vs 2.4% placebo; 86% of treated participants lost at least 5% of body weight [1]. Human (phase 3): the largest, longest-running dataset of the three, since Ozempic’s 2017 approval.
Tirzepatide: the dual agonist that outperformed semaglutide head-to-head
SURMOUNT-1 reported up to 22.5% mean weight loss at 72 weeks (15 mg) vs 3.1% placebo [3]. Human (phase 3): more decisive, SURMOUNT-5, a direct head-to-head trial, found tirzepatide produced 20.2% weight loss vs 13.7% for semaglutide over 72 weeks in the same population [4]. Tirzepatide’s added GIP-receptor activity appears to drive that gap, per receptor-binding studies [5].
Compound Universe take: 20.2% vs 13.7% is the clearest data point here: not a trial against placebo, but tirzepatide beating semaglutide in the same patients. That’s the strongest head-to-head evidence either approved drug has, and it’s the bar retatrutide’s unproven numbers get judged against.
Retatrutide: the investigational triple agonist
Retatrutide’s phase 2 trial reported a mean 17.5% reduction at 24 weeks and up to 24.2% at 48 weeks, the largest of the three to date [2]. Human (phase 3, topline): Lilly’s TRIUMPH-1 program reported topline results near 28% weight loss at 80 weeks in 2026, though those figures come from a press release, not a peer-reviewed paper [6]. Retatrutide has no brand name and stays investigational pending its full phase 3 program and an FDA filing.
How the three GLP-1 medicines differ in mechanism
Receptor count changes what each drug does, not just how strong it is. GLP-1 agonism slows gastric emptying and blunts appetite signals in the brain. Tirzepatide’s added GIP activity appears to improve insulin sensitivity and fat metabolism beyond GLP-1 alone [5]. Retatrutide’s added glucagon-receptor activity raises energy expenditure on top of appetite suppression, the proposed reason for its larger numbers [2].
Semaglutide activates only GLP-1, likely why its ceiling sits below the multi-receptor compounds. Retatrutide’s glucagon-receptor activity is the least understood in humans, since glucagon signaling touches liver glucose output in ways still being studied.
Read this before comparing numbers: This page explains the trial evidence and receptor biology behind retatrutide, tirzepatide, and semaglutide; it is not medical or dosing advice, and it does not recommend starting, stopping, or switching any of these drugs. Tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) are FDA-approved prescription drugs; retatrutide is investigational and not approved. Compounded versions of these medicines are tightly restricted under current FDA rules (see status below), and any decision about dose or product must come from a licensed prescriber.
| Compound | Primary mechanism | Evidence maturity | Regulatory status (US) |
|---|---|---|---|
| Semaglutide | GLP-1 receptor agonism | Human phase 3 plus years of post-approval data | FDA-approved brand drug; compounding narrowly restricted |
| Tirzepatide | Dual GIP + GLP-1 receptor agonism | Human phase 3, incl. head-to-head trial | FDA-approved brand drug; compounding narrowly restricted |
| Retatrutide | Triple GIP + GLP-1 + glucagon receptor agonism | Human phase 2 complete; phase 3 topline only | Investigational; no FDA approval; no legal compounding pathway |
Want the tirzepatide/semaglutide head-to-head on its own page?
Legal and compounding status: why “buying” any of these is not simple
Compounding rules have shifted repeatedly since 2023: mass compounding of copycat semaglutide and tirzepatide is no longer permitted the way it was during the shortages.
Shortage wind-down timelines for tirzepatide and semaglutide
| Compound | Shortage declared resolved | 503A deadline | 503B deadline |
|---|---|---|---|
| Tirzepatide | December 19, 2024 | February 18, 2025 | March 19, 2025 |
| Semaglutide | February 21, 2025 | April 22, 2025 | May 22, 2025 |
| Retatrutide | Not applicable | No legal compounding pathway | No legal compounding pathway |
Past those dates, only narrow, patient-specific medical-necessity compounding is legal, not the mass “essentially a copy” production of the shortage years [7].
Proposed bulk-substance exclusion
In April 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from compounders’ bulk substances list; the comment window closed June 30, 2026, with a final rule pending [7]. The FDA has also issued 2026 warning letters to telehealth sellers; “research use only” is not a legal shield for a product sold for human use.
Retatrutide’s separate problem
Retatrutide sits outside this conversation entirely: no approval, no legal compounding pathway, so anything sold as “retatrutide” is an unregulated research chemical, not a monitored drug. Readers on a prescribed pen needing injector-unit arithmetic can use Compound Universe’s dosage and reconstitution calculator; it does not suggest what to take.
Compound Universe take: The table above is the real decision point here: two of these three, tirzepatide and semaglutide, are legal brand prescriptions today, and the mass-compounded versions that made them cheap in 2023-2024 are gone on a fixed calendar. Retatrutide was never part of that arrangement; it has no approval to compound around. This comparison is really about which two are obtainable through a licensed prescriber now.
Key takeaways
- Semaglutide: single-receptor baseline, longest track record, 14.9% weight loss (STEP 1) [1].
- Tirzepatide: adds GIP, beat semaglutide directly: 20.2% vs 13.7% head-to-head [4].
- Retatrutide: adds glucagon, largest phase 2 numbers, still no FDA approval (July 2026) [2].
- Only semaglutide and tirzepatide are FDA-approved; both face restricted compounding, retatrutide has none.
- More receptors tracks with more weight loss, but also a shorter safety record.
Frequently asked questions
Is retatrutide better than tirzepatide and semaglutide?
Retatrutide produced larger weight loss in its own phase 2 trial, but hasn’t faced either drug head-to-head, and it isn’t FDA-approved [2][3].
What is the main difference between tirzepatide and semaglutide?
Semaglutide activates only GLP-1; tirzepatide activates GLP-1 and GIP. In a direct trial, tirzepatide produced greater weight loss, about 20% versus 14% [4].
Is retatrutide FDA-approved yet?
No. As of July 2026 it remains investigational. Its developer reported phase 3 topline results and expects to file later in 2026, with a possible 2027 decision [6].
Why does retatrutide target three receptors instead of one or two?
Glucagon-receptor activity was added on top of GLP-1 and GIP because glucagon signaling raises energy expenditure, the proposed reason for retatrutide’s larger numbers [2].
Can I get compounded retatrutide, tirzepatide, or semaglutide legally?
Compounded tirzepatide and semaglutide are legal only in narrow, patient-specific medical-necessity cases since 2025. Retatrutide has no legal pathway either.
Do all three work the same way in the body?
No. All three slow gastric emptying and reduce appetite via GLP-1 activity, but tirzepatide adds GIP effects on insulin and fat metabolism, and retatrutide adds glucagon effects on energy expenditure [5][2].
Want retatrutide’s live FDA filing status?
The retatrutide vs tirzepatide vs semaglutide comparison sits at the center of incretin pharmacology, where GLP-1 agonism, GIP co-activation, and glucagon signaling each drive a piece of the weight-loss and glycemic picture, alongside the FDA tracks governing brand approval, 503A/503B compounding, and bulk-substance exclusion; Compound Universe follows all three against the trial literature and the Federal Register so the comparison reflects evidence and law, not marketing claims.
Weighed side by side, retatrutide vs tirzepatide vs semaglutide reads less as a rivalry than a timeline: semaglutide proved the GLP-1 approach works, tirzepatide showed a second receptor beats it, and retatrutide is testing whether a third beats both.
Explore next: are peptides legal?
References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002. PMID 33567185. DOI 10.1056/NEJMoa2032183.
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315. DOI 10.1056/NEJMoa2301972.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216. PMID 35658024.
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. PMID 40353578. DOI 10.1056/NEJMoa2416394.
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020. PMID 32730231. DOI 10.1172/jci.insight.140532.
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline results, May 2026). Press release, not yet peer-reviewed. (VERIFY) exact journal citation once TRIUMPH-1 is published.
- U.S. Food and Drug Administration. FDA press announcements and Federal Register notices on 503A/503B compounding enforcement discretion and bulk drug substance exclusions for semaglutide, tirzepatide, and liraglutide (2025-2026). (VERIFY) specific Federal Register citation numbers before publish.